FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582102932> ?p ?o ?g. }

• W2582102932 abstract "Abstract Abstract 3194 Introduction: Using T2* Magnetic Resonance (MR) a randomized placebo controlled study from Sardinia demonstrated combination therapy with deferiprone and desferrioxamine (DFP+DFO) significantly more effective than DFO in improving myocardial iron. One non-randomized study from Sardinia and one observational study from Greece seem to confirm for DFP+DFO therapy the most rapid clearance of cardiac iron. No data are available in literature about prospective comparisons on cardiac iron and function and liver iron in TM patients treated with DFP+DFO versus DFP and DFO in monotherapy. The aim of our multi-centre study was to assess prospectively in a large clinical setting the efficacy of the DFP+DFO versus DFP and DFO in TM patients by quantitative MR. Methods: Among the 1135 TM patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network we selected those with an MR follow up study at 18±3 months who had been received one chelator alone between the 2 MR scans We evaluated prospectively the 51 patients treated with DFP+DFO versus the 39 patients treated with DFP and the 74 patients treated. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Results: The dosages were: combined therapy DFP 61.9±24.3 mg/kg per 6.1±1.4 days/week and DFO 40.7±6.0 per 3.5±1.1 days/week; DFP 73±13 mg/kg per 6.1±1.4 days/week; DFO 40.7±6.5 per 5.4±0.93 days/week. Excellent/good levels of compliance were comparable in the DFP+DFO (90.2%) versus DFP (94.9%) and DFO (95.9%) groups. The percentage of patients who maintained a normal global heart T2* value (≥20 ms) was comparable between DFP+DFO (96%) versus (100%) and DFO (98.1%) groups. Among the patients with myocardial iron overload at baseline (global heart T2*<20 ms), in all three groups there was a significant improvement in the global heart T2* values (combination: P=0.001; deferiprone: P=0.015 and desferrioxamine: P=0.007) and a significant reduction in the number of segments with an abnormal T2* value (combination: P=0.004; deferiprone: P=0.012 and desferrioxamine: P=0.002). Only in the deferiprone group there was a significant improvement in the left ventricular (LV) ejection fraction (EF) (P=0.045) while improvement in the right ventricular (RV) EF was significant in both combination (P=0.024) and deferiprone (P=0.001) groups. The changes in the global heart T2* as well as in biventricular function were not significantly different in DFO+DFP versus DFO or DFP groups (Table 1). After correction for influential covariates statistically different at baseline (global heart, age and HIC), the changes in global heart T2* values between the combination and the desferrioxamine groups became statistically different (P=0.014). Among the patients with hepatic iron at baseline (T2*<9.2 ms), the improvement in the liver T2* values was significant in the combination and in the desferrioxamine groups (combination: 4.9±6.0 ms P<0.0001; deferiprone: 2.1±4.8 ms P=0.070 and desferrioxamine: 2.0±3.5 ms P=0.010). The increase in liver T2* values was higher in combination versus deferiprone group, with a P-value near to the statistically significance (P=0.062); after covariates adjustment for the variable statistically different at baseline (serum ferritin) the significance was reached (P=0.043). The increase in liver T2* values was significant higher in combination than in desferrioxamine group (P=0.008), even after covariates adjustment. Conclusions: Prospectively in TM patients at the dosages used in the clinical practice combined DFP+DFO showed superior reduction in myocardial iron only versus the DFO in monotherapy and it did not show better improvement in biventricular function in comparison to DFO and DFP monotherapy. On the other hand, combined DFP+DFO was significantly more effective in the reduction of the liver iron versus DFO and DFP in monotherapy. Disclosures: Pepe: Novartis: Speakers Bureau; Apotex: Speakers Bureau; Chiesi: Speakers Bureau. Off Label Use: Association of two chelators commercially available in order to obtain a higher efficacy." @default.
• W2582102932 created "2017-02-03" @default.
• W2582102932 creator A5002668943 @default.
• W2582102932 creator A5004702687 @default.
• W2582102932 creator A5010606798 @default.
• W2582102932 creator A5011385057 @default.
• W2582102932 creator A5014591808 @default.
• W2582102932 creator A5016528606 @default.
• W2582102932 creator A5021358009 @default.
• W2582102932 creator A5025860412 @default.
• W2582102932 creator A5047841124 @default.
• W2582102932 creator A5054539855 @default.
• W2582102932 creator A5063303269 @default.
• W2582102932 creator A5071683844 @default.
• W2582102932 creator A5084125832 @default.
• W2582102932 creator A5085351555 @default.
• W2582102932 creator A5086243404 @default.
• W2582102932 creator A5086986768 @default.
• W2582102932 creator A5090506270 @default.
• W2582102932 date "2011-11-18" @default.
• W2582102932 modified "2023-09-30" @default.
• W2582102932 title "Prospective Comparison on Cardiac and Hepatic Iron and Cardiac Function by MR in Thalassemia Major Patients Treated with Combination Deferiprone–Desferrioxamine Versus Deferiprone and Desferrioxamine in Monoterapy," @default.
• W2582102932 doi "https://doi.org/10.1182/blood.v118.21.3194.3194" @default.
• W2582102932 hasPublicationYear "2011" @default.
• W2582102932 type Work @default.
• W2582102932 sameAs 2582102932 @default.
• W2582102932 citedByCount "0" @default.
• W2582102932 crossrefType "journal-article" @default.
• W2582102932 hasAuthorship W2582102932A5002668943 @default.
• W2582102932 hasAuthorship W2582102932A5004702687 @default.
• W2582102932 hasAuthorship W2582102932A5010606798 @default.
• W2582102932 hasAuthorship W2582102932A5011385057 @default.
• W2582102932 hasAuthorship W2582102932A5014591808 @default.
• W2582102932 hasAuthorship W2582102932A5016528606 @default.
• W2582102932 hasAuthorship W2582102932A5021358009 @default.
• W2582102932 hasAuthorship W2582102932A5025860412 @default.
• W2582102932 hasAuthorship W2582102932A5047841124 @default.
• W2582102932 hasAuthorship W2582102932A5054539855 @default.
• W2582102932 hasAuthorship W2582102932A5063303269 @default.
• W2582102932 hasAuthorship W2582102932A5071683844 @default.
• W2582102932 hasAuthorship W2582102932A5084125832 @default.
• W2582102932 hasAuthorship W2582102932A5085351555 @default.
• W2582102932 hasAuthorship W2582102932A5086243404 @default.
• W2582102932 hasAuthorship W2582102932A5086986768 @default.
• W2582102932 hasAuthorship W2582102932A5090506270 @default.
• W2582102932 hasConcept C126322002 @default.
• W2582102932 hasConcept C141071460 @default.
• W2582102932 hasConcept C142724271 @default.
• W2582102932 hasConcept C188816634 @default.
• W2582102932 hasConcept C204787440 @default.
• W2582102932 hasConcept C27081682 @default.
• W2582102932 hasConcept C2776517179 @default.
• W2582102932 hasConcept C2776672577 @default.
• W2582102932 hasConcept C2777218474 @default.
• W2582102932 hasConcept C2777799968 @default.
• W2582102932 hasConcept C71924100 @default.
• W2582102932 hasConcept C90924648 @default.
• W2582102932 hasConceptScore W2582102932C126322002 @default.
• W2582102932 hasConceptScore W2582102932C141071460 @default.
• W2582102932 hasConceptScore W2582102932C142724271 @default.
• W2582102932 hasConceptScore W2582102932C188816634 @default.
• W2582102932 hasConceptScore W2582102932C204787440 @default.
• W2582102932 hasConceptScore W2582102932C27081682 @default.
• W2582102932 hasConceptScore W2582102932C2776517179 @default.
• W2582102932 hasConceptScore W2582102932C2776672577 @default.
• W2582102932 hasConceptScore W2582102932C2777218474 @default.
• W2582102932 hasConceptScore W2582102932C2777799968 @default.
• W2582102932 hasConceptScore W2582102932C71924100 @default.
• W2582102932 hasConceptScore W2582102932C90924648 @default.
• W2582102932 hasLocation W25821029321 @default.
• W2582102932 hasOpenAccess W2582102932 @default.
• W2582102932 hasPrimaryLocation W25821029321 @default.
• W2582102932 hasRelatedWork W1973468651 @default.
• W2582102932 hasRelatedWork W1997119525 @default.
• W2582102932 hasRelatedWork W2002260518 @default.
• W2582102932 hasRelatedWork W2007465152 @default.
• W2582102932 hasRelatedWork W2014978771 @default.
• W2582102932 hasRelatedWork W2021356362 @default.
• W2582102932 hasRelatedWork W2042087520 @default.
• W2582102932 hasRelatedWork W2061877805 @default.
• W2582102932 hasRelatedWork W2064596825 @default.
• W2582102932 hasRelatedWork W2093134125 @default.
• W2582102932 hasRelatedWork W2377247008 @default.
• W2582102932 hasRelatedWork W2474026417 @default.
• W2582102932 hasRelatedWork W2552030324 @default.
• W2582102932 hasRelatedWork W2555739694 @default.
• W2582102932 hasRelatedWork W2557312282 @default.
• W2582102932 hasRelatedWork W2562435108 @default.
• W2582102932 hasRelatedWork W2582414527 @default.
• W2582102932 hasRelatedWork W2587698004 @default.
• W2582102932 hasRelatedWork W2808828885 @default.
• W2582102932 hasRelatedWork W3205153815 @default.
• W2582102932 isParatext "false" @default.
• W2582102932 isRetracted "false" @default.
• W2582102932 magId "2582102932" @default.
• W2582102932 workType "article" @default.